Part: 12         Session: 145678910111213141516171819202122         Page 732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792 of 999

patients and prevents viral infections in cancer patients who are getting it. Dr. Gutterman at M.D. Anderson in Houston hasn't seen any viral diseases in his patients, which is most rare. And he's seen two cases of shingles reversed.

Well, he's very enthusiastic.

He's very experienced.

Very enthsiastic about this?

Oh, very, very enthusiastic.

Now, you've got these people on the West Coast going. Anywhere else that you instigated?

Yes. Hoffman La Roche and Merck. Now, I'm sure that there are other -- the blood banks in New York and at Portland, Oregon, are very interested, and I'm hoping that the American Cancer Society will immediately begin to support them with the second helping of their appropriation now, to continue their interferon work. They've appropriated a million eight hundred thousand dollars this June, to continue their efforts.

This is on top of the two million?

Yes, on top of the two million. But that's just to continue that. Now, the people at the University of Wisconsin have started to use it on breast cancer patients and are already seeing important responses.

How did they happen to start using it in Wisconsin?

Well, because they applied for the interferon from the American Cancer Society.